262 related articles for article (PubMed ID: 33801886)
21. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
22. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
Yan S; Vandewalle N; De Beule N; Faict S; Maes K; De Bruyne E; Menu E; Vanderkerken K; De Veirman K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694201
[TBL] [Abstract][Full Text] [Related]
23. Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy.
Mikolajczyk A; Mitula F; Popiel D; Kaminska B; Wieczorek M; Pieczykolan J
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626092
[TBL] [Abstract][Full Text] [Related]
24. Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
Maimon A; Levi-Yahid V; Ben-Meir K; Halpern A; Talmi Z; Priya S; Mizraji G; Mistriel-Zerbib S; Berger M; Baniyash M; Loges S; Burstyn-Cohen T
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33848267
[TBL] [Abstract][Full Text] [Related]
25. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Smart SK; Vasileiadi E; Wang X; DeRyckere D; Graham DK
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30501104
[TBL] [Abstract][Full Text] [Related]
26. Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors.
Hedrich V; Breitenecker K; Djerlek L; Ortmayr G; Mikulits W
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771611
[TBL] [Abstract][Full Text] [Related]
28. Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis.
Al Kafri N; Hafizi S
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766614
[TBL] [Abstract][Full Text] [Related]
29. TAM kinases as regulators of cell death.
Post SM; Andreeff M; DiNardo C; Khoury JD; Ruvolo PP
Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):118992. PubMed ID: 33647320
[TBL] [Abstract][Full Text] [Related]
30. An insight into the TAM system in Alzheimer's disease.
Zhou S; Li Y; Zhang Z; Yuan Y
Int Immunopharmacol; 2023 Mar; 116():109791. PubMed ID: 36738678
[TBL] [Abstract][Full Text] [Related]
31. TAM Signaling in the Nervous System.
Burstyn-Cohen T; Hochberg A
Brain Plast; 2021; 7(1):33-46. PubMed ID: 34631419
[TBL] [Abstract][Full Text] [Related]
32. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
33. AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew.
Auyez A; Sayan AE; Kriajevska M; Tulchinsky E
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638349
[TBL] [Abstract][Full Text] [Related]
34. Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-CoV-2 Infection and COVID-19-Associated Immunothrombosis.
Tutusaus A; Marí M; Ortiz-Pérez JT; Nicolaes GAF; Morales A; García de Frutos P
Cells; 2020 Sep; 9(10):. PubMed ID: 32998369
[TBL] [Abstract][Full Text] [Related]
35. Resolving inflammation by TAM receptor activation.
Vago JP; Amaral FA; van de Loo FAJ
Pharmacol Ther; 2021 Nov; 227():107893. PubMed ID: 33992683
[TBL] [Abstract][Full Text] [Related]
36. The first laminin G-like domain of protein S is essential for binding and activation of Tyro3 receptor and intracellular signalling.
Al Kafri N; Ahnström J; Teraz-Orosz A; Chaput L; Singh N; Villoutreix BO; Hafizi S
Biochem Biophys Rep; 2022 Jul; 30():101263. PubMed ID: 35518197
[TBL] [Abstract][Full Text] [Related]
37. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Rios-Doria J; Favata M; Lasky K; Feldman P; Lo Y; Yang G; Stevens C; Wen X; Sehra S; Katiyar K; Liu K; Wynn R; Harris JJ; Ye M; Spitz S; Wang X; He C; Li YL; Yao W; Covington M; Scherle P; Koblish H
Front Oncol; 2020; 10():598477. PubMed ID: 33425754
[TBL] [Abstract][Full Text] [Related]
38. Mouse macrophages show different requirements for phosphatidylserine receptor Tim4 in efferocytosis.
Yanagihashi Y; Segawa K; Maeda R; Nabeshima YI; Nagata S
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):8800-8805. PubMed ID: 28768810
[TBL] [Abstract][Full Text] [Related]
39. Immuno-oncology: are TAM receptors in glioblastoma friends or foes?
Zhou Y; Wang Y; Chen H; Xu Y; Luo Y; Deng Y; Zhang J; Shao A
Cell Commun Signal; 2021 Jan; 19(1):11. PubMed ID: 33509214
[TBL] [Abstract][Full Text] [Related]
40. MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
Chen CJ; Liu YP
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33562150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
